Penile Cancer Market Report 2026

The penile cancer market size has grown strongly in recent years. It will grow from $25.86 billion in 2025 to $27.8 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to limited awareness and screening, delayed diagnosis, reliance on conventional surgery and chemotherapy, insufficient specialized treatment centers, fragmented patient data.

The penile cancer market size is expected to see strong growth in the next few years. It will grow to $37.41 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to rising adoption of immunotherapy and biological treatments, increasing use of personalized medicine approaches, expansion of early detection programs, growth of telemedicine and remote monitoring, increasing investment in penile cancer research and awareness. Major trends in the forecast period include increasing use of ai for early diagnosis and risk assessment, growing adoption of genomics-based targeted therapies, integration of cloud and big data for patient management, use of iot-enabled devices for monitoring treatment outcomes, implementation of smart manufacturing in biological therapy production.

The rising incidence of penile cancer is expected to drive the growth of the penile cancer market in the coming years. Penile cancer involves the development of malignant cells in the tissues of the penis. An increase in disease incidence leads to higher demand for diagnostic procedures, surgical interventions, and supportive care services, thereby influencing overall market growth. For instance, in January 2023, according to data shared by the American Cancer Society Inc., a US-based voluntary health organization, approximately 2,050 new cases of penile cancer and about 470 related deaths were expected to be reported in 2023. Therefore, the increasing incidence of penile cancer is contributing to the growth of the penile cancer market.

The expanding geriatric population is also expected to propel the growth of the penile cancer market going forward. The geriatric population includes older adults, among whom penile cancer is more commonly observed, as the risk of developing the disease rises with age. Treatment options for penile cancer in this population typically include surgery, radiation therapy, and targeted therapy. Growth in the elderly population increases susceptibility to penile infections and related conditions that can elevate cancer risk. For instance, in February 2025, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, the global population aged 60 years and older is projected to increase from 1.1 billion in 2023 to 1.4 billion by 2030. Therefore, the rise in the geriatric population is driving the growth of the penile cancer market.

Major companies operating in the penile cancer market are focusing on innovative approaches such as advanced cancer clinical trials to address unmet medical needs and improve patient outcomes. Advanced cancer trials involve evaluating new treatments, therapies, or drugs in patients with advanced-stage cancer to assess their safety and effectiveness. For example, in May 2023, the ECOG-ACRIN Cancer Research Group, a US-based scientific organization, enrolled 100 patients in the International Penile Advanced Cancer Trial (InPACT), which aims to offer new treatment possibilities for individuals with advanced penile cancer. This research initiative focuses on advanced stages of the disease and evaluates novel therapies, surgical techniques, and interventions to enhance treatment outcomes and quality of life, while advancing medical understanding of this rare and serious condition.

Major companies operating in the penile cancer market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Bristol‑Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Novartis AG, F Hoffmann‑La Roche Ltd, Johnson & Johnson, AbbVie Inc., GlaxoSmithKline plc, BeiGene Ltd., Iovance Biotherapeutics Inc, Lisata Therapeutics Inc, Halozyme Therapeutics Inc, Sotio Biotech, Sanofi S A, Genmab A S, Otsuka Pharmaceutical Co Ltd, Adaptimmune Therapeutics plc, Apceth Biopharma GmbH & Co KG.

North America was the largest region in the penile cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the penile cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the penile cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the penile cancer market by increasing the cost of imported chemotherapy drugs, biological therapy agents, and diagnostic equipment, affecting hospitals and clinics in regions such as North America and Europe. While tariffs have temporarily raised treatment costs, they have also encouraged local production, innovation in cost-effective therapies, and improved supply chain resilience for critical drugs and medical devices.

The penile cancer market research report is one of a series of new reports that provides penile cancer market statistics, including penile cancer industry global market size, regional shares, competitors with a penile cancer market share, detailed penile cancer market segments, market trends and opportunities, and any further data you may need to thrive in the penile cancer industry. This penile cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Penile cancer is a condition characterized by the formation of malignant cells in the tissues of the male reproductive organ that is responsible for urination and sexual function. The disease may develop in different areas of the penis, including the glans, foreskin, shaft, or surrounding tissues.

The primary types of penile cancer include squamous cell carcinoma of the penis, adenocarcinoma of the penis, melanoma of the penis, basal cell carcinoma of the penis, and sarcoma of the penis. Squamous cell carcinoma is the most common form and arises from squamous cells, which are flat, thin cells that line the surface of the penis. Penile cancer is treated using various therapeutic approaches such as radiation therapy, chemotherapy, biological therapy, and surgery, and is diagnosed through procedures including biopsy, ultrasound, and imaging tests. These treatments and diagnostic methods are utilized across multiple settings, including hospitals, clinics, and others.

The penile cancer market includes revenues earned by entities by providing services such as screening and diagnosis, treatment options, psychosocial support, multidisciplinary treatment, surgical interventions, and radiation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.